Turkish Journal of Internal Medicine

Journal Information
EISSN : 2687-4245
Current Publisher: Nizameddin Koca (10.46310)
Total articles ≅ 26
Filter:

Latest articles in this journal

Murat Ozturk , Atilla Satir, Bulent Gul, Nizameddin Koca
Turkish Journal of Internal Medicine, Volume 2, pp 113-117; doi:10.46310/tjim.810295

Feyza Sönmez Topcu, Umit Koc
Turkish Journal of Internal Medicine, Volume 2, pp 127-130; doi:10.46310/tjim.772179

Elif Nalan Tolgay, Meral Seferoğlu , Özlem Taşkapilioğlu, Ömer Faruk Turan
Turkish Journal of Internal Medicine, Volume 2, pp 105-112; doi:10.46310/tjim.771364

Ayşegül Oruç, Mehmet Fethullah Aydin, Abdulmecit Yildiz, Mahmut Yavuz, Mustafa Güllülü, Kamil Dilek, Alparslan Ersoy
Turkish Journal of Internal Medicine, Volume 2, pp 118-122; doi:10.46310/tjim.768289

Ernest Herbert, Dominique Fournier
Turkish Journal of Internal Medicine, Volume 2, pp 98-104; doi:10.46310/tjim.768866

Meral Seferoğlu , Nizameddin Koca, Barış Şensoy
Turkish Journal of Internal Medicine, Volume 2, pp 123-126; doi:10.46310/tjim.770428

İbrahim Akdağ, Alparslan Ersoy
Turkish Journal of Internal Medicine, Volume 2, pp 83-90; doi:10.46310/tjim.766086

Abstract:
Methotrexate (MTX) is widely used in the treatment of both rheumatoid arthritis (RA) and psoriatic arthritis (PA) with a side effect of pancytopenia. However, very few cases of severe pancytopenia caused by low-dose MTX therapy have been described in chronic kidney disease. Pancytopenia occurred after using a single dose of MTX in three patients with chronic kidney dysfunction. While one patient died due to sepsis and multiple organ failure, the others recovered. The severity of MTX-inducedpancytopenia in our cases was likely related to the underlyingkidney disease. These cases suggest that uremic patients may develop severe fatal bone marrow toxicity even with a single dose of MTX. Therefore, close blood count monitoring after MTX treatment in this population would be beneficial.
Canan Ersoy
Turkish Journal of Internal Medicine, Volume 2, pp 59-65; doi:10.46310/tjim.768962

Abstract:
Diabetes mellitus is a chronic disease characterized by hyperglycemia causing damage to the vascular system. The lungs with a large vascular network are also predisposed to diabetes’ vascular damage. Diabetes may lead to pulmonary parenchymal damage besides alterations in the vascular system and the alveolar-capillary membrane. Symptoms and damage caused by diabetes are usually underdiagnosed because of the large pulmonary reserves. Pulmonary involvement in diabetes is an area that draws attention in recent years. This attention increases especially with the new Coronavirus disease-2019 (COVID-19) pandemic when the worse prognosis is detected in diabetics. In this review, possible mechanisms leading to pulmonary involvement and pulmonary function abnormalities in diabetes, the interaction between COVID-19 and diabetes concerning lungs, and the basic effects of antidiabetic drugs on the lungs are discussed in the view of the literature.
Canan Ersoy
Turkish Journal of Internal Medicine, Volume 2, pp 66-72; doi:10.46310/tjim.732932

Abstract:
Osteoporosis is a systemic skeletal disorder characterized by an imbalanced bone turnover leading to low bone mass and bone microarchitecture disruption that increase the risk of fractures. It is the most common metabolic bone disorder seen in the World due to prolongation of life. In this review, the basic aspects for the evaluation, diagnosis, treatment and follow-up of osteoporosis is discussed in the view of the literature.
Mustafa Narmanli, Vildan Gürsoy, Rıdvan Ali, Yılmaz Özen
Turkish Journal of Internal Medicine, Volume 2, pp 73-77; doi:10.46310/tjim.767946

Abstract:
Although splenectomy is markedly effective treatment modality at early period in adult chronic immune thrombocytopenia (ITP), long-term outcomes are still controversial. The aim of this study was to determine long-term effectiveness and reliability of splenectomy in ITP and to identify factors influencing on long-term response. The study included 100 ITP patients who underwent splenectomy in our General Surgery Department between 1980 and 2004. Parameters including gender, age, platelet count, comorbid diseases, antiplatelet antibody positivity and long-term effect of medical treatment on response to splenectomy were considered. Owing to advances in treatment protocols, ITP has become a more benign disease and need for splenectomy has been decreased. However, splenectomy is a highly effective in second-line treatment. Based on our results, it was seen that open or laparoscopic splenectomy with low morbidity and mortality rates is an appropriate treatment modality for long-term control of chronic ITP in cases requiring splenectomy. Age and postoperative platelet count were identified as significant prognostic and predictive factors for long-term response to splenectomy.
Back to Top Top